Clinical trials: CD - Crohn's Disease
Crohn Disease
Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission of Crohn's Disease
This protocol is designed to compare the effectiveness of two dietary interventions for patients with Crohn's disease (CD): the Specific Carbohydrate Diet (SCD) and a Mediterranean style diet (MSD) that has been demonstrated to…
- Trial name
- DINE-CD (NCT03058679)
- Testing
- Diet
- Where
- 35 sites in United States
- Volunteers
- 197 people
- Sponsor
- University of Pennsylvania
Crohn Disease
A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease
The purpose of this study is to examine the safety and efficacy of CNTO 1275 in participants with active Crohn's Disease.
- Trial name
- NCT00265122
- Testing
- Ustekinumab 90 mg, Ustekinumab 4.5 mg/kg
- Where
- 57 sites in United States, Belgium and 1 more
- Volunteers
- 131 people
- Sponsor
- Centocor, Inc.
Perianal Fistula, Crohn's Disease
Seeded Cells on Matrix Plug Treating Crohn's Perianal Fistulas (STOMP-II)
A Phase II study to assess the safety and efficacy of AVB-114 in treatment of complex Crohn's perianal fistulas in subjects with quiescent rectal disease and whose fistula has failed to respond to biologic or conventional…
- Trial name
- NCT04847739
- Testing
- Seton Placement, AVB-114
- Where
- 15 sites in United States
- Volunteers
- 60 people
- Sponsor
- Avobis Bio, LLC
Crohn´s Disease
9 mg Budesonide Once Daily (OD) Versus 3 mg Budesonide Three Times Daily (TID) in Active Crohn's Disease
This study aims to evaluate the efficacy of 9 mg budesonide once daily (OD) versus 3 mg budesonide three-times daily (TID) for the induction of remission in Crohn's disease.
- Trial name
- NCT01086553
- Testing
- budesonide
- Where
- Germany
- Volunteers
- 471 people
- Sponsor
- Dr. Falk Pharma GmbH
Crohn's Disease
Drug-Disease Interaction in Crohn's Disease
Objective: To determine the effect of C-reactive protein (CRP) status, and infliximab treatment on the pharmacodynamics and pharmacokinetics of verapamil, a model drug for L-type calcium channel blocking, in Crohn's disease (CD)…
- Trial name
- NCT01261286
- Testing
- verapamil
- Where
- Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Alberta
Ulcerative Colitis (UC), Crohn's Disease
A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).Crohn's disease (CD) is a long-lasting condition causing inflammation…
- Trial name
- NCT04254783
- Testing
- Risankizumab, Cytochrome P450 (CYP) Substrates
- Where
- 6 sites in United States, Germany and 1 more
- Volunteers
- 20 people
- Sponsor
- AbbVie
Crohn's Disease
A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease
The purpose of the study is to assess efficacy, safety and tolerability of 2 dose regimens of certolizumab pegol
- Trial name
- NCT04643483
- Testing
- Certolizumab pegol, Adalimumab
- Sponsor
- UCB Biopharma SRL
Nephrolithiasis, Hyperoxaluria
Use of Oral Probiotics to Reduce Urinary Oxalate Excretion
The purpose of this study was to determine the effect of two probiotic preparations (Agri-King Synbiotic and Oxadrop) on urinary oxalate excretion in patients with mild hyperoxaluria.
- Conditions
- Nephrolithiasis, Hyperoxaluria, Crohn's Disease
- Trial name
- NCT00587041
- Testing
- Oxadrop, Agri-King Synbiotic (AKSB)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Mayo Clinic
Pediatric Crohns Disease
Clinical Hypnosis in Pediatric Crohn's Disease
Inflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC), is a chronic, immune-mediated disease increasingly prevalent in youth.
- Trial name
- HypnoCrohns (NCT03809195)
- Testing
- Clinical Hypnosis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Vanderbilt University Medical Center
Crohn's Disease
Study to Determine Relationship Between Serum Infliximab and Efficacy in Luminal Crohn's Disease Patients
To assess the relationship between the change in Crohn's Disease Activity Index (CDAI) scores and trough serum infliximab concentration in subjects who are scheduled to receive infliximab infusions at an interval of 8 weeks.
- Trial name
- X-Sectional (NCT00676988)
- Where
- 2 sites in Canada
- Volunteers
- 327 people
- Sponsor
- University of Western Ontario, Canada
Crohn's Disease, Inflammatory Bowel Disease
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
This study (UNITI-2) will compare the effects (both positive and negative) of an initial treatment with ustekinumab to a placebo over 8 weeks in patients with moderately to severely active Crohn's disease.
- Conditions
- Crohn's Disease, Inflammatory Bowel Disease, IBD, Colitis
- Trial name
- NCT01369342
- Testing
- Group 2 ustekinumab 130 mg, Group 3: ustekinumab approximately 6 mg/kg
- Where
- 220 sites in United States, Australia and 20 more
- Volunteers
- 640 people
- Sponsor
- Janssen Research & Development, LLC
Inflammatory Bowel Diseases, Children, Only
A Treat-to-target Strategy Using Pan-enteric Capsule Endoscopy (PCE) in Paediatric Crohn's Disease (CD).
This prospective, interventional study aims this to determine the efficacy and safety of a PCE-based treat-to-target strategy in order to achieve Mucosal Healing (MH) and deep remission (DR) of pediatric Crohn's Disease (CD) over…
- Trial name
- PCE (NCT03161886)
- Testing
- Pan-enteric Capsule Endoscopy (PCE)
- Volunteers
- 48 people
- Sponsor
- Azienda Policlinico Umberto I
Stenosis; Bowel, Crohn Disease
Clinical Trial to Evaluate if the Laparoscopic Administration of Cells Derived From the Fatty Tissue Can Improve the Inflammatory Stenosis in Patient With Crohn's Disease
A phase II, national, multicenter, uncontrolled and open trial to evaluate the feasibility and safety of laparoscopic administration of adipose derived allogenic mesenchymals stem cells (adMSC), for the treatment of patients with…
- Trial name
- MEIC (NCT05521672)
- Testing
- Adipose derived allogenic mesenchymal stem cells (adAMSC)
- Where
- 3 sites in Spain
- Volunteers
- 2 people
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Rheumatoid Arthritis, Spondyloarthritis
Evaluation of the Switch From the Original Infliximab to Its Biosimilar in Daily Practice at Cochin Hospital
The purpose of this study is to evaluate the effectiveness of the switch from the original infliximab ( REMICADE®) to its biosimilar (INFLECTRA®) in all the patients at Cochin hospital receiving REMICADE® for either a rheumatic…
- Conditions
- Rheumatoid Arthritis, Spondyloarthritis, Crohn's Disease, Uveitis
- Trial name
- SIC (NCT02998398)
- Testing
- Switch from REMICADE® to INFLECTRA®
- Where
- France
- Volunteers
- 262 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Crohn's Disease
MICISPORT Survey : Questionnaire
This study offers a questionnaire to patients with Crohn's disease in order to assess their physical activity and / or sport as well as their eating habits in order to assess the impact of these lifestyle habits on activity and…
- Trial name
- MICISPORT (NCT04297566)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Montpellier
Crohn's Disease
Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease
The purpose of the study is to evaluate an intravenous (by injection) investigational medication to treat moderate to severe inflammatory, nonstricturing, nonpenetrating Crohn's disease.
- Trial name
- NCT00267722
- Testing
- Visilizumab
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Facet Biotech
Perianal Fistula Due to Crohn's Disease
Expanded Access Protocol for STOMP-II Patients Who Were Unable to Receive Treatment Subsequent to Adipose Tissue Collection
The goal of this Expanded Access Protocol is to provide expanded access of AVB-114 to patients who had their fat tissue collected as part of a clinical trial (STOMP-II), but who were subsequently not treated with AVB-114 because…
- Trial name
- EAP-STOMP2 (NCT06509828)
- Testing
- AVB-114
- Sponsor
- Avobis Bio, LLC
Ulcerative Colitis, Crohn's Disease
Study on Cannabinoid Receptor Expression in Gastrointestinal Diseases
The purpose of the study is to investigate phospholipid ligands and their receptors in inflammatory bowel diseases and colon cancer.
- Conditions
- Ulcerative Colitis, Crohn's Disease, Colon Cancer
- Trial name
- NCT02735941
- Where
- Austria
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
Crohn Disease
A Study of a FimH Blocker, EB8018, in Crohn's Disease Patients
Enterome small molecule drug EB8018 is a first-in-class FimH blocker to be studied in Crohn's disease patients. The proposed indication for EB8018, as an add-on therapy, will be the treatment of adult patients suffering from…
- Trial name
- EBFIM117 (NCT03709628)
- Testing
- EB8018 (First-in-class FimH blocker)
- Where
- 5 sites in Austria, France and 2 more
- Volunteers
- 8 people
- Sponsor
- Enterome
Crohn's Disease
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the bowels.
- Trial name
- AFFIRM (NCT06063967)
- Testing
- Risankizumab SC
- Where
- 179 sites in United States, Argentina and 18 more
- Volunteers
- 289 people
- Sponsor
- AbbVie
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.